This project is designed to apply the immunohistochemical assay (ICA) for estrogen (ER) and progesterone receptors (PgR) in a prospective, nonrandomized clinical trial. Previously untreated, elderly women with breast cancer 5.0 cm or greater, and with ER and/or PgR positive tumors by ICA will be placed on an 8 week course of tamoxifen. Such patients are usually treated with some type of therapy before surgery in order to reduce tumor bulk. To determine endocrine response, tumor size and axillary lymph nodes will be measured by caliper and by nuclear magnetic imaging before and after therapy. ICA will be performed on fine needle aspirates (FNA) and/or core needle biopsies on both freshly frozen and formalin fixed, paraffin-embedded tissue. Biochemical ER and PgR on open biopsy specimens will be performed in the laboratory of Dr. William L. McGuire in San Antonio, Texas. All assay results will be correlated with clinical endocrine response in order to determine the procedure with the best sensitivity, specificity and positive predictive value. The ability to perform accurate receptor assays on initial tumor obtained by FNA or core biopsy, especially on routinely processed tissue, should materially reduce false negative assay results such as may be obtained when mastectomy specimens are analyzed. Expenses and logistical problems incurred in obtaining an open biopsy for diagnosis and receptor analysis with freezing, and transport of frozen tissue, would be obviated, since in-patient or ambulatory surgery suites are not needed for FNA or needle biopsy, formalin fixed. Such an assay would also be of use in determining receptor content in women diagnosed with very small lesions, now commonly seen, as well as those with Stage IV disease where adequate amounts of tissue for biochemistry are often unavailable. Furthermore, ICA on routinely processed specimens would permit retrospective assay of archival pathology specimens. This would be of research value and useful for women where no steroid receptor assay was initially performed. Finally, ICAs will be quantified by television imaging and compared with qualitative and semi- quantified results as determined by visual inspection.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA023623-10A3
Application #
3166196
Study Section
Reproductive Endocrinology Study Section (REN)
Project Start
1978-04-01
Project End
1995-04-30
Budget Start
1992-05-01
Budget End
1993-04-30
Support Year
10
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Suny Downstate Medical Center
Department
Type
Schools of Medicine
DUNS #
068552207
City
Brooklyn
State
NY
Country
United States
Zip Code
11203
Prins, G S; Sklarew, R J; Pertschuk, L P (1998) Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. J Urol 159:641-9
Pertschuk, L P; Feldman, J G; Kim, Y D et al. (1996) Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays. Cancer 77:2514-9
Pertschuk, L P; Masood, S; Simone, J et al. (1996) Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol Oncol 63:28-33
Pertschuk, L P; Schaeffer, H; Feldman, J G et al. (1995) Immunostaining for prostate cancer androgen receptor in paraffin identifies a subset of men with a poor prognosis. Lab Invest 73:302-5
Pertschuk, L P; Kim, Y D; Axiotis, C A et al. (1994) Estrogen receptor immunocytochemistry: the promise and the perils. J Cell Biochem Suppl 19:134-7
Pertschuk, L P; Macchia, R J; Feldman, J G et al. (1994) Immunocytochemical assay for androgen receptors in prostate cancer: a prospective study of 63 cases with long-term follow-up. Ann Surg Oncol 1:495-503
Pertschuk, L P; Feldman, J G; Kim, D S et al. (1993) Steroid hormone receptor immunohistochemistry and amplification of c-myc protooncogene. Relationship to disease-free survival in breast cancer. Cancer 71:162-71
Sklarew, R J; Bodmer, S C; Pertschuk, L P (1991) Comparison of microscopic imaging strategies for evaluating immunocytochemical (PAP) steroid receptor heterogeneity. Cytometry 12:207-20
Pertschuk, L P; Kim, D S; Nayer, K et al. (1990) Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer 66:1663-70
Sklarew, R J; Bodmer, S C; Pertschuk, L P (1990) Quantitative imaging of immunocytochemical (PAP) estrogen receptor staining patterns in breast cancer sections. Cytometry 11:359-78

Showing the most recent 10 out of 19 publications